An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

M Sagud, D Breznoscakova, A Celofiga, J Chihai… - Schizophrenia …, 2024 - Elsevier
Objectives To compare the prevalence, regulations, and pharmacovigilance practices of
clozapine use in Eastern European countries (except Russia). Methods Questionnaires and …

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: can the regulations be relaxed?

PFJ Schulte, SRT Veerman, B Bakker… - Schizophrenia …, 2024 - Elsevier
After the introduction of clozapine eight Finnish patients died after developing
agranulocytosis. Clozapine was withdrawn from the market and only reintroduced with strict …

[HTML][HTML] Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

C De las Cuevas, EJ Sanz, JA Gross, CU Correll… - Schizophrenia …, 2024 - Elsevier
Background Pharmacovigilance studies indicate clozapine history is marked by adverse
drug reactions (ADRs). Objective In a 2021 article, the United Kingdom (UK) had> 90% of …

Optimizing antidepressant and clozapine co-prescription in clinical practice: a systematic review and expert recommendations

H Verdoux, C Quiles, J de Leon - Schizophrenia Research, 2024 - Elsevier
Objectives To synthesize the information relevant for clinical practice on clozapine-
antidepressant co-prescription concerning pharmacokinetic drug-drug interactions (DDI) …

Clozapine and neutrophil response in patients of African descent: a six-month, multinational, prospective, open-label clinical trial

DL Kelly, M Glassman, I Wonodi, G Vyas… - Schizophrenia …, 2024 - Elsevier
Introduction Clozapine is the most effective antipsychotic for treatment-resistant
schizophrenia, but it is markedly underutilized, particularly in the US Black population, partly …

Clozapine for persons with neurodevelopmental disorders: a systematic review and expert recommendations for clinical practice

H Verdoux, C Quiles, J de Leon - Expert Review of Clinical …, 2024 - Taylor & Francis
Introduction We aimed to synthesize the information on the risks and benefits of clozapine
prescription for resistant challenging behavior in persons with neurodevelopmental …

Current practice for clozapine-induced leukopenia in Japanese psychiatric hospitals: A nationwide survey

T Niitsu, N Yasui-Furukori, K Inada, T Kanazawa… - Schizophrenia …, 2024 - Elsevier
Clozapine is an atypical antipsychotic used for treatment-resistant schizophrenia. In Japan,
its use requires management by a blood monitoring system called the Clozaril Patient …

Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice

H Verdoux, C Quiles, J de Leon - Expert Opinion on Drug …, 2024 - Taylor & Francis
Introduction Antiseizure medication (ASM) add-on to clozapine may be efficient to target
clozapine-resistant mood or psychotic symptoms or clozapine-related adverse drug …

Overcoming clozapine's adverse events: a narrative review of systematic reviews and meta-analyses

T Tanzer, B Pham, N Warren, M Barras… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Clozapine is the gold standard treatment for treatment resistant schizophrenia,
however adverse events remain a clinical challenge. Areas Covered This review presents a …

Promoting safer and wider worldwide use of clozapine

J de Leon - Schizophrenia Research, 2024 - Elsevier
This issue focuses on the past, the present and the future of clozapine. Of the 43 clozapine
articles, nine are historical articles dealing with the past, 29 deal with the present and five …